Glad to see so many friends in top 15. Keep the influence going!
Toni Choueiri, MD@DrChoueiri
Metrics from #ASCO26 via @OncoAlert @ASCO
English
Ulka Vaishampayan
214 posts
Remarkable work! Novel prognostic marker in prostrate cancer
Emmanuel Antonarakis@EAntonarakis
Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims @VanAllenLab @nikolausschultz europeanurology.com/action/showPdf…
English
Congrats for bringing this forward. @tompowles1
Very attractive regimen to limit the EV therapy.
Toni Choueiri, MD@DrChoueiri
JUST IN: VOLGA Phase III is (+)=>Neoadjuvant Durva+EV and adjuvant Durva alone showed EFS & OS benefit. The shorter period of EV is a very attractive option! @DanaFarber_GU @OncoAlert @OncBrothers @AstraZeneca @tompowles1 @AUC3_Official
English
JKCVHL is the journal that provides open access with no publication fees.
Kidney Cancer@KidneyCancer
🎉Incredibly proud of this publication and grateful for the leadership of @salvolarosa @BataiKen @PavlosMsaouel and other contributors who made this important research possible. Our paper is out today with FREE access! 🔗mdpi.com/2072-6694/18/9…
English
Ulka Vaishampayan retweetledi
DAY Two of OncoAlert 🚨 Coverage of #IKCSEU26
Provider Perceptions of Cure in Renal Cell Cancer Presented by Ms. Dena Battle🇺🇸 of @kcCURE
RCC specialists demonstrate notable hesitancy in using the term “cure,” even in clinical contexts where long-term outcomes may justify it. This reluctance reflects not only clinical uncertainty but also parallels similar reservations among patients. The absence of a standardized definition contributes to inconsistent communication, potentially affecting expectations and decision-making. Establishing clearer, consensus-driven terminology around “cure” in RCC could enhance transparency, improve physician–patient alignment, and support more informed shared decision-making. Addressing this linguistic and conceptual gap may ultimately strengthen trust and facilitate more meaningful discussions about prognosis and treatment goals in renal cell carcinoma care. #KidneyCancer
@KidneyCancer Jean-Christophe Bernhard @univbordeaux @AlbigesL @gustaveroussy @TiansterZhang @Dr_SabyGeorge @ZakhariaYousef @ERPlimackMD @Ric_Campi @DrIacovelli @RebuzziSara @weoncologists @GEVaughan1 @salvolarosa @DrYukselUrun #KidneyCancer @daniyal_jafree @EJonasch @IKCCorg @sophiemerrick1 @BarbaraJereczek @ESTRO_RT @ZakhariaYousef @kuraoncology @Selcuk__Erdem @drulkav @RCCadvocate
English
Kicking off the IKCS Europe meeting with Think tank. Exciting discussions have started.
Kidney Cancer@KidneyCancer
Always a dynamic discussion during KCA Think Tank meetings where many of our most impactful programs and moonshot initiatives have sparked! Thanks to our #IKCSEU26 TT presenters #LarsLund @grantissimus @srossi725 @MichaelStaehler @RCCadvocate #axelbex @salvolarosa @GEVaughan1
English
English
Congrats @BradMcG04 and @DrCCutler on your recent awards!
@DanaFarber @DanaFarberNews @harvardmed
English
Ulka Vaishampayan retweetledi
We joined @FOX26Houston this week to talk kidney cancer 🧡
KCA’s Gretchen Vaughan and patient advocate Josh Silva shared Josh’s journey, key symptoms, and how to support the KCA 81K Challenge — amplifying patient voices and raising awareness where it matters most!
English
Grateful to join this wonderful mtg @PGrivasMDPhD and @chandlerpark and be a part of this panel.
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏@CParkMD
Albert, great discussion with a powerhouse prostate cancer panel—Dr. Maha Hussain, Dr. Sandy Srinivas, Dr. Dan Petrylak, Dr. Ulka Vaishampayan, and Dr. Ben Maughan 👏 We learned so much from your case discussion at #MatosGU26. This is how we all get better. @AJangMD @PGrivasMDPhD @mecmededucation 💡 💥 Loved this moment. Great job Albert! #Oncology #MedEd #ProstateCancer @DanielPetrylak @sandysrimd @DrVaishampayan @maughanonc @oncodaily @urotoday @Larvol
English
#MaTOS meeting
Petros Grivas@PGrivasMDPhD
Awesome talk by @MVossMD on non clear cell RCC covering different histology types: evolving landscape but need specific trials for each histology! @ZakhariaYousef @CParkMD @EddieSantosMD @LuisRaezMD @mecmededucation @ADESAIONCMD @sandysrimd @ChadTangMD @HHammersMD @JadChahoud
English
Biofront opening soon. #rogelcancercenter #swog
Pedro C Barata, MD MSc FACP@PBarataMD
@LauraEsfeller @drulkav @montypal @BrianShuch @SWOG We’re so excited to have you @LauraEsfeller and @swog team @montypal @DrVaishampayan pushing this important study forward - very soon (April 1st) close to you! 🫵 #GU26
English
Ulka Vaishampayan retweetledi
@LauraEsfeller @drulkav @montypal @BrianShuch @SWOG We’re so excited to have you @LauraEsfeller and @swog team @montypal @DrVaishampayan pushing this important study forward - very soon (April 1st) close to you! 🫵 #GU26
English
Pls activate Swog 2419 the BIOFRONT trial. First large randomized trial testing combo of probiotic with immune therapy ( Ipi and nivo or Cabo and nivo or Len and pembro) in Frontline RCC @ esfeller
Laura Esfeller@LauraEsfeller
Finally, a clinical trial I’ve been working on for 2 years w/ @PBarataMD @drulkav @montypal @BrianShuch & many others @SWOG opens for enrollment very, very soon, and I couldn’t be more excited. S2419 (BIOFRONT) will be the first SWOG trial and the first phase III trial anywhere
English
Ulka Vaishampayan retweetledi
🌉 #GU26 is in the books for team KCA! Ahead of #KidneyCancerAwarenessMonth, amazing to see the work advocates, researchers, and more are doing together to drive #kidneycancer science forward - proud to contribute to the efforts 🧡
So much for patients to be hopeful about!
English
Thanks for this comprehensive list. @DrChoueiri
Toni Choueiri, MD@DrChoueiri
ASCO GU 2026 – Top 15 Trials with Potential Practice Impact @ASCO #GU26
English
Commendable to help define response and continue advancement in MIBC
Andrea Necchi, MD, FASCO@AndreaNecchi
Happy to share a vision with my friend @UroDocAsh on our continuing efforts to optimize treatments and outcomes for patients with MIBC #bladdercancer #clinicalresearch @SanRaffaeleMI @MyUniSR @urotoday @IBCG_BladderCA @OncoAlert @ASCO #DailyNews Developing Clinical Complete Response Definitions for Muscle-Invasive Bladder Cancer dailynews.ascopubs.org/do/developing-…
English